Evident Vascular, a medical technology startup developing an intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, recently announced that it has launched with a US$35 million Series A financing from Vensana Capital.
“The impetus to launch Evident Vascular was born out of the Vensana team’s extensive experience in the vascular space. Our team has partnered with entrepreneurs across multiple emerging therapeutic categories in vascular disease over the last two decades, including endovascular aortic aneurysm grafts, drug-coated balloons, venous stents, arterial tacks, and thrombectomy devices,” said Justin Klein, managing partner at Vensana Capital. “IVUS is ripe for innovation. Evident Vascular is addressing a critical need in the IVUS market, making it an ideal company to add to our vascular technology innovations.”
IVUS is a transcatheter intravascular imaging technique used to acquire images from inside blood vessels to evaluate vascular disease and guide interventional treatment. Although IVUS has steadily made inroads, predominantly in coronary interventions, robust clinical trial data supporting utilisation in both coronary and peripheral interventions are fueling future market growth. Peripheral arterial and venous disease use is now the largest and fastest-growing segment of IVUS procedures in the USA, an Evidenct Vascular press release reports.
“While there have been significant advances in the options to treat peripheral vascular disease, the diagnostic tools needed to accurately and appropriately guide delivery of these therapies have lagged. We see a tremendous opportunity to create a next-generation IVUS platform that addresses the needs of vascular interventionalists, and we are excited to be partnering with an outstanding team to launch Evident Vascular,” added Cynthia Yee, principal at Vensana Capital.
“Legacy IVUS platforms were originally designed primarily for coronary procedures and secondarily for peripheral vascular applications. Shortcomings in image quality, interpretation, and workflow have limited the widespread adoption of IVUS despite its clinical benefit, and there has been minimal innovation to address these limitations,” said Howard Rosen, CEO and co-founder, Evident Vascular. “Along with my co-founders, chief technology officer Patrick Phillips and chief product officer Danielo Piazza, our team is pioneering the future of intravascular imaging with a platform optimised for peripheral vascular procedures that will enable improved image interpretation guidance, and ease of use enhancements throughout the clinical workflow.”